Article Data

  • Views 240
  • Dowloads 102

Original Research

Open Access

The value of mesothelin in the diagnosis and follow-up of surgically treated ovarian cancer

  • Naian Qiao1,*,
  • Haiying Li2

1,Department of Radiotherapy

2Division of Ultrasonography, Shandong University Qilu Hospital, Jinan (China)

DOI: 10.12892/ejgo340212 Vol.34,Issue 2,March 2013 pp.163-165

Published: 24 March 2013

*Corresponding Author(s): Naian Qiao E-mail: haiyingql@163.com.

Abstract

Objective: To assess the value of serum mesothelin concentration for diagnosis of ovarian cancer and for monitoring the therapeutic effect of surgical treatment. Materials and Methods: The study consisted of 42 patients with ovarian cancer undergoing surgery, 48 with benign ovarian tumors, and 49 healthy controls. Blood was drawn pre-operatively and one month post-operatively to test serum mesothelin levels. Results: Mesothelin values were higher in the ovarian cancer group compared to controls and higher preoperatively vs post-operatively in the ovarian cancer group. For the diagnosis of ovarian cancer, the positive predictive value of serum mesothelin was 80.5%, the negative predictive value was 81.6%, sensitivity was 78.6%, and specificity was 83.3%. Conclusion: Serum mesothelin is increased in ovarian cancer, has high-specificity, and can be used in the pre-operative diagnostic evaluation for ovarian cancer.

Keywords

Mesothelin; Ovarian cancer.

Cite and Share

Naian Qiao, Haiying Li. The value of mesothelin in the diagnosis and follow-up of surgically treated ovarian cancer. European Journal of Gynaecological Oncology. 2013. 34(2);163-165.

References

[1] Jemal A., Twari R.C., Murray T., Ghafoor A., Samuels A., Ward E. et al.: “Cancer statistics, 2004”. CA Cancer J. Clin., 2004, 54, 8.

[2] Young R.C., Walton L.A., Ellenberg S.S., Homesley H.D., Wilbanks G.D., Decker D.G. et al.: “Adjuvant therapy in Stage I and Stage II epithelial ovarian cancer”. N. Engl. J. Med., 1990, 322, 1021.

[3] Bast R.C., Klug T.L., St John E., Jenison E., Niloff J.M., Lazarus H. et al.: “A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer”. N. Engl. J. Med., 1983, 309, 883.

[4] Jacobs I.J., Skates S.J., MacDonald N., Menon U., Rosenthal A.N., Davies A.P. et al.: “Screening for ovarian cancer: a pilot randomised controlled trial”. Lancet, 1999, 353, 1207.

[5] Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M. et al.: “Use of proteomic patterns in serum to identify ovarian cancer”. Lancet, 2002, 359, 572.

[6] Sasaroli D., Coukos G., Scholler N.: “Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet?”. Biomark Med., 2009, 3, 275.

[7] Cohen L.S., Escobar P.F., Scharm C., Glimco B., Fishman D.A.: “Three dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction”. Gynecol. Oncol., 2001, 82, 40.

[8] Hellström I., Raycraft J., Hayden-Ledbetter M., Ledbetter J.A., Schummer M., McIntosh M. et al.: “The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma”. Cancer Res., 2003, 63, 3695.

[9] Havrilesky L.J., Whitehead C.M., Rubatt J.M., Cheek R.L., Groelke J., He Q. et al.: “Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence”. Gynecol. Oncol., 2008, 110, 374.

[10] Anastasi E., Marchei G.G., Viggiani V., Gennarini G., Frati L., Reale M.G.: “HE4: a new potential early biomarker for the recurrence of ovarian cancer”. Tumour Biol., 2010, 31, 113.

[11] Hellström I., Hellström K.E.: “Two novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma”. Expert. Opin. Med. Diagn., 2011, 5, 227.

[12] Palmer C., Duan X., Hawley S., Scholler N., Thorpe J.D., Sahota R.A. et al.: “Systematic evaluation of candidate blood markers for detecting ovarian cancer”. PLoS One, 2008, 3, e2633.

[13] Creaney J., Yeoman D., Naumoff L.K., Hof M., Segal A., Musk A.W. et al.: “Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma”. Thorax, 2007, 62, 569.

[14] Creaney J., Musk A.W., Robinson B.W.: “Sensitivity of urinary mesothelin in patients with malignant mesothelioma”. J. Thorac. Oncol., 2010, 5, 1461.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top